IL2 and melanoma: In order to reduce the IL-2-related side effects, a variety of modifications to the high-dose IL-2 regimens have been tested in patients with melanoma, including alterations of dose, schedule and route, as well as chemical alterations of IL-2 molecular structure that alter its cellular targets.